The influence of immunosuppressive drugs on vascular endothelial growth factor production in relation to VEGF -1154 G and -2578 C genotypes

Iranian Journal of Immunology

Volumn 7, Issue 4, 2010, Pages 217-225

  Mohammadi, Mojgan ^a,b   Day, Philip J R ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Gene polymorphisms; Immunosuppressive drugs; VEGF

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RAPAMYCIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; VEGF GENE;

EID: 79952689595     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69: 4-10
2. Ciołkiewicz M, Kuryliszyn-Moskal A, Klimiuk PA. Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients. Clin Rheumatol. 2010; 29:175-180.
3. Watson CJ, Webb NJ, Bottomley MJ. Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000; 12:1232-5.
4. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002; 13:260-4.
5. Mohammadi M, Bazrafshani MR, Day PJ, Ollier WE. Vascular Endothelial Growth Factor production is regulated by gene polymorphisms. Iran J Immunol. 2009; 6:119-29.
6. Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am. J Transplant. 2003; 3:1211-5.
7. Josefiak K, Arns W, Merkel F, Weber M. Pseudomembraneous colitis under therapy with mycophenolate mofetil following pancreas-kidney double transplantation. Nephrol Dial Transplant. 2001; 16:1959-60.
8. Allison AC. Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47:85-118.
9. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm. 2000; 57:437-48.
10. Pham SM, Qi XS, Mallon SM, Kaplon RJ, Bauerlein EJ, Katariya K, et al. Sirolimus and tacrolimus in clinical cardiac transplantation. Transplant Proc. 2002; 34:1839-42.
11. Neff GW, Montalbano M, Slapak-Green G, Meyer D, Berney T, Safdar K, et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc. 2003; 35:3029-31
12. Briggs WA, Gao ZH, Xing JJ, Gimenez LF, Samaniego MD, Scheel PJ, et al. Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both. J Clin Pharmacol. 1996; 36:931-7.
13. Briggs WA, Gao ZH, Xing JJ, Scheel PJ, Gimenez LF, Choi MJ, et al. Differential suppression of dialysis patients' lymphocyte IFN-gamma production by glucocorticoids and cyclosporine. Cytokine. 1996; 8:804-8.
14. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998; 8:283-9.
15. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther. 2004; 76:545-56.
16. Yu S, Wu L, Jin J, Yan S, Jiang G, Xie H, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation. 2006; 81:46-51.
17. Hashida T. Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther. 2001: 69:308-16.
18. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006; 82:1074-84.
19. Weimer R, Mytilineos J, Feustel A, Preiss A, Daniel V, Grimm H, et al. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation. 2003; 75:2090-9.
20. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007; 81:228-34.